oral semaglutide weight loss fda Novo Nordisk's weight-loss pill wins approval New Oral Weight Loss Pill

Diabetes Care 2019;42:226271.PubMedPMC 30

When to Seek Immediate Medical Attention Severe, persistent abdominal pain (possible pancreatitis) Vision changes or eye pain (possible retinopathy) Signs of severe dehydration (dizziness, dark urine, confusion) Allergic reaction (rash, difficulty breathing, swelling) Severe hypoglycemia (confusion, sweating, rapid heartbeat) Persistent vomiting lasting more than 24 hours GLP-1 drugs are being increasingly obtained by individuals without a prescription, which makes side effects more dangerous than ever

Rybelsus contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycaemic control in adults with type 2 diabetes mellitus

Additionally, GLP-1 RAs with established CV benefitsspecifically liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatideare recommended for patients with T2DM and ASCVD to reduce CV events, regardless of baseline or target HbA1c levels or concurrent glucose-lowering therapy (Class I, LoE A)